Skip to main content
Premium Trial:

Request an Annual Quote

Stem Cell Sciences Shareholders Support Sale to StemCells

NEW YORK (GenomeWeb News) – Shareholders of UK-based Stem Cell Sciences have voted in favor of selling the firm's assets to Stem Cell Sciences.

The vote is the most recent step in SCS' plans to sell off its assets and delist from the AIM and Australian Securities Exchange.

The firms announced the nearly $5 million deal earlier this month.

The transaction will provide Palo Alto, Calif.-based StemCells, which is focused on developing tissue-derived cellular products for therapeutic uses, with cell-based drug discovery technologies. Among the products StemCells gains through the deal are automated systems for production and manipulation of stem and progenitor cells, gene insertion technology for drug screening and for applications in cell and gene therapy, the SC Proven media formulation and reagent business, and SCS' licensing deals with firms, such as Merck and Millipore.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.